Excellergy to be acquired by Novartis for up to USD 2 billion to advance potentially first-in-class trifunctional effector cell response inhibitors

– Acquisition brings together Excellergy's differentiated trifunctional allergic effector cell response inhibitors (ECRIs) and the development expertise of Novartis, with a total potential transaction value of up to $2 billion – – Exl-111 is a potentially first-in-class allergic trifunctional ECRI targeting the IgE axis and is currently in Phase 1 development – PALO ALTO, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Excellergy, a biotechnology company developing a novel class of allergy therapeutics, today an ...